News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shire Human Genetic Therapies Signs Exclusive Marketing and Distribution Deal With Samaritan Pharmaceuticals, Inc. (SPHC) to Launch REPLAGAL for Fabry Disease in Greece and Cyprus


5/22/2007 12:16:57 PM

LAS VEGAS, May 22, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, is pleased to announce it has signed a second exclusive marketing and distribution agreement, with Shire Human Genetic Therapies AB to launch and sell REPLAGAL(r) (agalsidase alfa), a European approved drug, for Fabry Disease, in Greece and Cyprus.

Read at Prime Zone

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES